Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Acta Oncologica

Volumn 48, Issue 3, 2009, Pages 391-400

  Vikman, Sofia ^a   Sommaggio, Roberta ^a   De La Torre, Manuel ^a   Berg, Kjell ^b   Essand, Magnus ^a   Giandomenico, Valeria ^a,b   Loskog, Angelica ^a   Ttterman, Thomas H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER ANTIBODY; CD4 ANTIGEN; CYTOKINE; DYE; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BLOOD; CANCER INFILTRATION; CANCER PATIENT; CARCINOID; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE STATUS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MIDGUT; PHENOTYPE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STAINING; TH1 CELL; TUMOR; VALIDATION STUDY; CASE CONTROL STUDY; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; INTESTINE TUMOR; LIVER TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; METASTASIS; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD4; CARCINOID TUMOR; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; T-LYMPHOCYTES, REGULATORY;

EID: 65349163589     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802438495     Document Type: Article

References (47)

1. Renqvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;/50:/3-15.
2. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;/23:/2346-57.
3. Morgan RA, Dudley ME,Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;/314:/126-9.
4. Tuettenberg A, Becker C, Huter E, Knop J, Enk AH, Jonuleit H. Induction of strong and persistent Melan A/ MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer 2006;/118:/2617-27.
5. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;/24:/ 3089-94.
6. Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004;/10:/2944-53.
7. Ferrantini M, Capone I, Marincola FM, Parmiani G, Belardelli F. International meeting ''Immunotherapy of cancer: Challenges and needs''. Cancer Immunol Immunother 2007;/56:/581-5.
8. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nature Rev Cancer 2005;/5:/263-74.
9. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006;/6:/295-307.
10. Wilczynski JR, Radwan M, Kalinka J. The characterization and role of regulatory T cells in immune reactions. Front Biosci 2008;/13:/2266-74.
11. Jonuleit H, Schmitt E. The regulatory T cell family: Distinct subsets and their interrelations. J Immunol 2003;/171:/ 6323-7.
12. Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4-Treg cells. J Exp Med 2006;/203:/1701-11.
13. Hartigan-O Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4-regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Method 2007;/319:/41-52.
14. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(-)CD25(-) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;/61:/4766-72.
15. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;/169:/2756-61.
16. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4-CD25-regulatory T cells in patients with gastrointestinal malignancies. Cancer 2003;/98:/1089-99.
17. Miller AM, Lundberg K, Özenci V, Banham AH, Hellström M, Egevad L, et al. CD4-CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;/177:/7398-405.
18. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmström P-U, Tö tterman TH. Human bladder carcinoma is dominated by T regulatory cells and Th1 inhibitory cytokines. J Urol 2007;/177:/353-8.
19. Papewalis C, Wuttke M, Jacobs B, Domberg J, Willenberg H, Baehring T, et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008;/40:/108-16.
20. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;/10:/942-9.
21. Petersen RP, Carpa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, et al. Tumor infiltrating Foxp3-regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;/107:/2866-72.
22. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;/24:/5373-80.
23. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, et al. FOXP3-regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;/13:/902-11.
24. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, et al. Prognostic value of tumor-infiltrating CD4-T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;/12:/465-72.
25. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005;/12:/1005-16.
26. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;/100:/8372-7.
27. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;/100:/4712-7.
28. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4-2H4-suppressor-inducer T cells. Cancer Res 1988;/48:/1671-5.
29. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;/115:/3623-33.
30. A°kerström G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol 2005;/89:/161-9.
31. Van der Horst-Schrivers ANA, Machteld Wymenga AN, Links TP, Willemse PHB, Kema IP, de Vries EGE. Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology 2004;/80(Suppl 1):/28-32.
32. .ö berg K. Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005;/17:/386-91.
33. Schott M, Seissler J. Dendritic cell vaccination: New hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol Metab 2003;/14:/156-62.
34. Vikman S, Essand M, Cunningham JL, de la Torre M, .ö berg K, Tö tterman TH, et al. Gene expression in midgut carcinoid tumors: potential targets for immunotherapy. Acta Oncol 2005;/44:/32-40.
35. Vikman S, Giandomenico V, Sommaggio R, .ö berg K, Essand M, Tö tterman TH. CD8-T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. Cancer Immunol Immunother 2008;/57:/ 399-409.
36. Chen W, Perruche S, Li J. CD4-CD25-T regulatory cells and TGF-beta in mucosal immune system: The good and the bad. Curr Med Chem 2007;/14:/2245-9.
37. Allez M, Mayer L. Regulatory T cells: Peace keepers in the gut. Inflamm Bowel Dis 2004;/10:/666-76.
38. Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and TR1 and TH3 regulatorycells. Nat Immunol 2001;/2:/671-2.
39. Zhang PJ, Furth EE, Cai X, Goldblum JR, Pascha TL, Min KW. The role of beta-catenin, TGF beta 3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Hum Pathol 2004;/35:/670-4.
40. Wimmel A, Wiedenmann B, Rosewicz S. Autocrine growth inhibition by transforming growth factor b-1 (TGFb-1) in human neuroendocrine tumor cells. Gut 2003;/52:/1308-16.
41. Zeutenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003;/97:/ 1609-15.
42. Chaudhry A, Funa K, .ö berg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993;/32:/107-14.
43. Beauchamp RD, Coffey RJ Jr, Lyons RM, Perkett EA, Townsend CM Jr, Moses HL. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 1991;/51:/ 5253-60.
44. Russo S, Boon JC, Kema IP, Willemse PH, den Boer JA, Korf J, et al. Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. Psychosom Med 2004;/66:/422-5.
45. Martinez A, Knappskog PM, Haavik J. A structural approach into human tryptophan hydroxylase and its implications for the regulation of serotonin biosynthesis. Curr Med Chem 2001;/8:/1077-91.
46. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;/117:/1147-54.
47. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor j-chain and induce a regulatory phenotype in naïve T cells. J Immunol 2006;/176:/6752-61.